Use the basic search or click on advanced for more search options.

Advanced Search Basic Search Advanced Search



Select publication to see the relevant sections.

Publication Date

    E.g., 2018-10-21
    E.g., 2018-10-21

Archive Search


1137 items
4:29 PM, Apr 13, 2018  |  BioCentury | Tools & Techniques

Personalizing prevention

PlaqueTec Ltd. is working to bring personalized medicine to the cardiovascular space with a device that samples local concentrations of molecules near atherosclerotic plaques. By using these samples to identify prognostic and predictive biomarkers, the...
3:07 PM, Mar 17, 2017  |  BioCentury | Tools & Techniques

Calibrating PD-L1

Flagship Biosciences Inc.’s Computational Tissue Analysis platform won’t provide a common cutoff point across the five major assays used to measure PD-L1 expression. But it could calibrate the output so that results from one assay...
4:51 PM, Feb 24, 2017  |  BioCentury | Tools & Techniques

Optimizing outreach

After spending six years developing and testing its technology, Prognos has officially launched its commercial tool that uses laboratory, imaging and other data to predict which patients are the best candidates for marketed therapies. Prior...
6:16 PM, Jan 20, 2017  |  BioCentury | Tools & Techniques

Hopes in the machine

Applying machine learning tools to drug R&D could usher in a new era of effective therapies targeting causative disease drivers, higher success rates in clinical trials and real-world tools to manage adherence, prevent adverse events...
6:56 PM, Nov 04, 2016  |  BioCentury | Tools & Techniques

Predicting reality

A new machine learning tool from GNS Healthcare Inc. that predicts the real-world effectiveness of new drug candidates could help companies design better postmarket studies and serve as a jumping-off point to help shape risk-sharing...
12:00 AM, Oct 31, 2016  |  BioCentury | Tools & Techniques

Slaying senescent cells

  With a whopper of a B round and a new publication demonstrating both a causal role of senescent cells in atherosclerosis, and a therapeutic effect of eliminating them, Unity Biotechnology Inc. is readying to push...
12:00 AM, Apr 11, 2016  |  BioCentury | Tools & Techniques

Stepping on the scale

By giving other companies' short-read sequencers the ability to perform long reads, 10x Genomics Inc. expects researchers will be able to fully unlock the genome. Co-founders CEO Serge Saxonov, COO and CTO Kevin Ness...
12:00 AM, Nov 23, 2015  |  BioCentury | Tools & Techniques

Editing CF

Vertex Pharmaceuticals Inc. and CRISPR Therapeutics AG are collaborating to see whether CRISPR's gene editing technology can succeed where gene therapies have come up short for cystic fibrosis. The technology is expected to produce more...
12:00 AM, Oct 05, 2015  |  BioCentury | Tools & Techniques

J&J intercepts Nextera

Johnson & Johnson's option deal with Nextera A/S could add another tool to the pharma's growing arsenal of T cell-based technologies for intercepting immunological diseases before they start. On Sept. 21, Nextera granted J&J's Janssen...
12:00 AM, Jun 29, 2015  |  BioCentury | Tools & Techniques

Watching disease

Google X's life sciences division has unveiled its latest project aimed at enabling proactive and preventive healthcare: a wristwatch that measures biometric and environmental data continuously to help guide disease diagnosis and treatment. In the near...